Is there a rationale to using leflunomide in early rheumatoid arthritis?

Clinical and Experimental Rheumatology

Volumn 23, Issue 3, 2005, Pages 404-412

  Dayer, Jean Michel ^a   Cutolo, Maurizio ^b  

^a UNIVERSITY HOSPITAL   (Switzerland)

^b UNIVERSITY OF GENOA   (Italy)

Author keywords

Cytokines IL 1 TNF; Early RA; Leflunomide; Monocyte T cell interactions

Indexed keywords

DIHYDROOROTATE DEHYDROGENASE; DISEASE MODIFYING ANTIRHEUMATIC DRUG; ETANERCEPT; INFLIXIMAB; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 6; INTERSTITIAL COLLAGENASE; LEFLUNOMIDE; METHOTREXATE; PROSTAGLANDIN E2; PYRIMIDINE; RECOMBINANT INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; SALAZOSULFAPYRIDINE; VASCULAR CELL ADHESION MOLECULE 1;

ANTIINFLAMMATORY ACTIVITY; CELL PROLIFERATION; CLINICAL TRIAL; CYTOKINE PRODUCTION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; ENZYME INHIBITION; HUMAN; IMMUNOMODULATION; MOLECULAR MECHANICS; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; SIDE EFFECT; T LYMPHOCYTE ACTIVATION;

ANTI-INFLAMMATORY AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; IMMUNOSUPPRESSIVE AGENTS; ISOXAZOLES; PROFESSIONAL PRACTICE; RHEUMATOLOGY;

EID: 20444501369     PISSN: 0392856X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (70)

1. CHOY EH, PANAYI CS: Cytokine pathways and joint inflammation in rheumatoid arthritis. N Engl J Med 2001; 344: 907-16.
2. DAYER J-M, BURGER D: Cell-cell interactions and tissue damage in rheumatoid arthritis. Autoimmunity Rev 2004; 3 (Suppl. 1): S14-S16.
3. DORNER T, EGERER K, FEIST E, BURMESTER GR: Rheumatoid factor revisited. Curr Opin Rheumatol 2004; 16: 246-53.
4. FIRESTEIN GS. The T cell cometh: interplay between adaptive immunity and cytokine networks in rheumatoid arthritis. J Clin Invest 2004; 114: 471-4.
5. CUTOLO M, SULLI A, SERIOLO B, VILLAGGIO B, STRAUB RH: New roles for estrogens in rheumatoid arthritis. Clin Exp Rheumatol 2003; 21: 687-90.
6. BIJLSMA JWJ, STRAUB RH, MASI AT, LAHITA RG, CUTOLO M: Neuroendocrine immune mechanisms in rheumatic diseases. Trends Immunol 2002; 23: 59-61.
7. Van BOEKEL MAM, VOSSENAAR ER, Van Den HOOGEN FHJ, Van VENROOIJ WJ: Autoantibody systems in rheumatoid arthritis: specificity, sensitivity and diagnostic value. Arthritis Res 2001; 4: 87-93.
8. HILL JA, SOUTHWOOD S, SETTE A, JEVNIKAR AM, BELL DA, CAIRNS E. Cutting edge: the conversion of arginine to citrulline allows for a high-affinity peptide interaction with the rheumatoid arthritis-associated HLA-DRB1*0401 MHC class II molecule. J Immunol 2003; 171: 538-41.
9. 3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J Immunol 1992; 149: 2040-6.
10. BURGER D, DAYER J-M: Cytokines, acute-phase proteins and hormones: IL-1 and TNF-α production in contact-mediated activation of monocytes by T lymphocytes. Ann NY Acad Sci 966: 2002; 464-73.
11. CUTOLO M: Macrophages as effectors of the immunoendocrinologic interactions in autoimmune rheumatic disease. Ann NY Acad Sci 1999; 876: 745-9.
12. REZZONICO R, BURGER D, DAYER J-M: Direct contact between T lymphocytes and human dermal fibroblasts or synoviocytes down-regulates types I and III collagen production via cell-associated cytokines. J Biol Chem 1998; 273: 18720-28.
13. CHIZZOLINI C, REZZONICO R, RIBBENS C, BURGER D, WOLLHEIM FA, DAYER J-M: Inhibition of type I collagen production by dermal fibroblasts upon contact with activated T cells. Different sensitivity to inhibition between systemic sclerosis and control fibroblasts. Arthritis Rheum 1998; 41: 2039-47.
14. VANDERBORGHT A, LINSEN L, THEWISSEN M, GEUSENS P, RAUS J, STINISSEN P: Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand mRNA expression in patients with rheumatoid arthritis and healthy controls. J Rheumatol 2004; 31: 1483-90.
15. HYKA N, DAYER J-M, MODOUX C, KOHNO T, EDWARDS III CK, ROUX-LOMBARD P, BURGER D: Apolipoprotein A-I inhibits the production of interleukin-1β and tumor necrosis factor-α by blocking contact-mediated activation of monocytes by T lymphocytes. Blood 2001; 97: 2381-9.
16. BURGER D, DAYER J-M: High-density lipoprotein-associated apolipoprotein A-I: the missing link between infection and chronic inflammation ? Autoimmunity Rev 2002; 1: 111-7.
17. ABE H, TSUBOI N, SUZUKI S, et al.: Anti-apolipoprotein A-1 autoantibody: characterization of monoclonal autoantibodies from patients with systemic lupus. J Rheumatol 2001; 28: 990-5.
18. VUILLEUMIER N, REBER G, JAMES R et al.: Presence of autoantibodies to apolipoprotein A-1 in patients with acute coronary syndrome further links autoimmunity to cardovascular disease. J Autoimmunity 2004; 23: 353-60.
19. CHERWINSKY HM, BYARS N, BALLARON SJ, NAKANO GM, YOUNG JM, RANSOM JT: Leflunomide interferes with pyrimidine nucleotide biosynthesis. Inflamm Res 1995; 44: 317-22.
20. CAO WW, KAO PN, CHAO AC, GARDNER P, NG J, MORRIS R: Mechanism of the anti-proliferative action of leflunomide does not block T-cell receptor-mediated signal transduction but its antiproliferative effects are antagonized by pyrimidine nucleosides. J Heart Lung Transplant 1995; 14: 1016-30.
21. FOX RI, HERRMANN ML, FRANGOU CG et al.: Short analytical review: mechanism of action for leflunomide in rheumatoid arthritis. Clin Immunol 1999; 93: 198-208.
22. WILLIAMSON RA, YEA CM, ROBSON PA et al.: Dihydroorotate dehydrogenase is a high affinity binding protein for A77 1726 and mediator of a range of biological effects of the immunomodulatory compound. J Biol Chem 1995; 270: 22467-72.
23. BREEDVELD FC, DAYER J-M: Leflunomide: mode of action in the treatment of rheumatoid arthritis. Ann Rheum Dis 2000; 59: 841-9.
24. CAO WW, KAO PN, AOKI Y, XU JC, SHORT-HOUSE RA, MORRIS RE: A novel mechanism of action of the immunomodulatory drug, leflunomide: augmentation of the immunosuppressive cytokine, TGF-β1, and suppression of the immunostimulatory cytokine, IL-2. Transplant Proc 1996; 28: 3079-80.
25. MANNA SK, AGGARWAL BB: Immunosuppressive leflunomide metabolite (A77 1726) blocks TNF-dependent nuclear factor-kB activation and gene expression. J Immunol 1999; 162: 2095-102.
26. DIMITROVA P, SKAPENKO A, HERRMANN ML, SCHLEYERBACH R, KALDEN JR, SCHULZE-KOOPS H: Restriction of de nove pyrimidine biosynthesis inhibits Th1 cell activation and promotes Th2 cell differentiation. J Immunol 2002; 169: 3392-9.
27. BURGER D, REZZONICO R, LI J-M et al.: Imbalance between interstitial collagenase (MMP-1) and tissue inhibitor of metalloproteinases-1 (TIMP-1) in synoviocytes and fibroblasts upon direct contact with stimulated T lymphocytes: involvement of membrane-associated cytokines. Arthritis Rheum 1998; 41: 1748-59.
28. VEY E, BURGER D, DAYER J-M: Expression and cleavage of tumor necrosis factor- and tumor necrosis factor receptors by human monocytic cell lines upon direct contact with stimulated T cells. Eur J Immunol 1996; 26: 2404-9.
29. DEAGE V, BURGER D, DAYER J-M: Exposure of T lymphocytes to leflunomide but not to dexamethasone favors the production by monocytic cells of interleukin-1 receptor antagonist and the tissue inhibitor of metalloproteinases-1 over that of interleukin-1β and metalloproteinases. Eur Cytokine Netw 1998; 9: 663-8.
30. KRAAN MC, REECE RJ, BARG EC et al.: Modulation of inflammation and metalloproteinase expression in synovial tissue by leflunomide and methotrexate in patients with active rheumatoid arthritis. Arthritis Rheum 2000; 4: 1820-30
31. CUTOLO M, SULLI A, GHIORZO P, PIZZORNI C, CRAVIOTTO C, VILLAGGIO B: Anti-inflammatory effects of leflunomide on cultured synovial macrophages from patients with rheumatoid arthritis. Ann Rheum Dis 2003; 62: 297-302.
32. GRISAR J, ARINGER M, KOLLER MD et al.: Leflunomide inhibits transendothelial migration of peripheral blood mononuclear cells. Ann Rheum Dis 2004; 63: 1632-37.
33. MILJKOVIC DJ, SAMARDZIC T, DRAKULIC D, STOSIC-GRUJICIC S, TRAJKOVIC V: Immunosuppressants leflunomide and mycophenolic acid inhibit fibroblast IL-6 production by distinct mechanisms. Cytokine 2002; 19: 181-6.
34. BURGER D, BEGUE-PASTOR N, BENAVENT S et al.: The active metabolite of leflunomide, A77 1726, inhibits the production of prostaglandin E2, matrix metalloproteinase 1 and interleukin 6 in human fibroblast-like synoviocytes. Rheumatology 2003; 42: 89-96.
35. ELKAYAM O, YARON I, SHIRAZI I, JUDOVITCH R, CASPI D, YARON M: Active leflunomide metabolite inhibits interleukin 1β, tumour necrosis factor a, nitric oxide, and metalloproteinase-3 production in activated human synovial tissue cultures. Ann Rheum Dis 2003; 62: 440-3.
36. HO CY, WONG CK, LI EK, TAM LS, LAM CW: Suppressive effect of combination treatment of leflunomide and methotrexate on chemokine expression in patients with rheumatoid arthritis. Clin Exp Immunol 2003; 133: 132-8.
37. PALMER G, BURGER D, MEZIN F et al.: The active metabolite of leflunomide, A77 1726, increases the production of IL-1 receptor antagonist in human synovial fibroblasts and articular chrondrocytes. Arthritis Res Ther 2004; 6: R181-9.
38. URUSHIBARA M, TAKAYANAGI H, KOGA T et al.: The antirheumatic drug leflunomide inhibits osteoclastogenesis by interfering with receptor activator of NF-kB ligand-stimulated induction of nuclear factor of activated T cells c1. Arthritis Rheum 2004; 50: 794-804.
39. KRAAN MC, SMEETS TJM, Van LOON MJ, BREEDVELD FC, DIJKMANS BAC, TAK PP: Differential effects of leflunomide and methotrexate on cytokine production in rheumatoid arthritis. Ann Rheum Dis 2004; 63: 1056-61.
40. WEINBLATT ME: The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999; 38 (Suppl. 2):19-23.
41. SMOLEN J, BREEDVELD F, STRAND S, KALDEN J, COHEN S, EMERY P: Efficacy of leflunomide in DMARD-naïve patients with early RA. Ann Rheum Dis 2002; Abstract Eular.
42. COMBE B, OED C: Higher efficacy of Leflunomide in methotrexate-naïve patients. Ann Rheum Dis 2003; Abstract Eular.
43. POOR G, STRAND V: Efficacy and safety of Leflunomide 10 mg versus 20 mg once daily in patients with active rheumatoidarthritis: multinational double-blind, randomized trial. Rheumatology 2004; 43: 744-9.
44. SCHIFF HM, STRAND V, OED C, LOEW-FRIEDRICH I: Leflunomide: efficacy and safety in clinical trials for the treatment of rheumatoid arthritis. Drugs of Today 2000; 36: 383-94.
45. KALDEN JR, SCHATTENKIRCHNER M, SÖRENSEN H et al.: The efficacy and safety of leflunomide in patients with active rheumatoid arthritis: a five-year followup study. Arthritis Rheum 2003; 48: 1513-20.
46. REECE RJ, KRAAN MC, RADJENOVIC A et al.: Comparative assessment of leflunomide and methotrexate for the treatment of rheumatoid arthritis, by dynamic enhanced magnetic resonance imaging. Arthritis Rheum 2002; 46: 366-72.
47. OSIRI M, SHEA B, ROBINSON V et al.: Leflunomide for the treatment of rheumatoid arthritis: a systematic review and metaanalysis. J Rheumatol 2003; 30: 1182-90.
48. SCOTT DL, STRAND V: The effects of disease-modifying anti-rheumatic drugs on the Health Assessment Questionnaire score. Lessons from the leflunomide clinical trials database. Rheumatology (Oxford) 2002; 41: 899-909.
49. STRAND V, COHEN S, SCHIFF M et al.: Treatment of active rheumatoid arthritis with leflunomide compared with placebo and methotrexate. Arch Intern Med 1999; 159: 2542-50.
50. EMERY P, BREEDVELD FC, LEMMEL EM et al.: A comparison of the efficacy and safety of leflunomide and methotrexate for the treatment of rheumatoid arthritis. Rheumatology (Oxford) 2000; 39: 655-65.
51. SMOLEN JS, KALDEN JR, SCOTT DL et al.: Efficacy and safety of leflunomide compared to placebo and sulfasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. Lancet 1999; 353: 259-266.
52. STRAND V, SCOTT DL, EMERY P, KALDEN JR, SMOLEN JS, CANNON GW, for the Leflunomide Rheumatoid Arthritis Investigators GROUPS: Physical function and health-related quality of life: Analysis of 2-year data from randomized, controlled studies of leflunomide, sulfasalazine, or methotrexate in patients with active rheumatoid arthritis. J Rheumatol 2005 (In press).
53. SHARP J, STRAND V, LEUNG H, HURLEY F, LOEW-FRIEDRICH I, on behalf of the LEFLUNOMIDE RHEUMATOID ARTHRITIS INVESTIGATORS GROUP: Treatment with leflunomide slows radiographic progression of rheumatoid arthritis. Arthritis Rheum 2000; 43: 495-505.
54. LARSEN A, KVIEN TK, SCHATTENKIRCHNER M et al. for the European Leflunomide Study Group: Slowing of disease progression in rheumatoid arthritis patients during long-term treatment with leflunomide or sulfasalazine. Scand J Rheumatol 2001; 30: 135-42.
55. Van Der HEIJDE D, KALDEN J, SCOTT D, SMOLEN J, STRAND V: Long-term evaluation of radiographic disease progression in a subset of patients with rheumatoid arthritis treated with leflunomide beyond 2 years. Ann Rheum Dis 2004; 63: 737-9.
56. WOLFE F, MICHAUD K, STEPHENSON B, DOYLE J: Toward a definition and method of assessment of treatment failure and treatment effectiveness: the case of leflunomide versus methotrexate. J Rheumatol 2003; 30: 1725-32.
57. ALETAHA D, EBERL G, NELL VP, MACHOLD KP, SMOLEN JS: Attitudes to early rheumatoid arthritis: changing patterns. Results of a survey. Ann Rheum Dis 2004; 63: 1269-75.
58. ZINK A, LISTING JD, KARY S et al.: Treatment continuation in patients receiving biologicals or conventional DMARD therapy. Ann Rheum Dis (published online 11 Feb 2005).
59. CANNON GW, HOLDEN W, JUHAERI J, DAI W, SCARAZZINI L, STANG P: Adverse events with disease modifying antirheumatic drugs (DMARD): a cohort study of leflunomide compared with other DMARD. J Rheumtol 2004; 31: 1906-11.
60. KREMER JM, CANNON G: Benefit/risk of leflunomide in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22 (Suppl. 35): S95-S100.
61. MARTIN K, BENTABERRY F, DUMOULIN C et al.: Effectiveness and safety profile of leflunomide in rheumatoid arthritis: actual practice compared with clinical trials. Clin Exp Rheumatol 2005; 23: 80-4.
62. KALDEN JR, SMOLEN JS, EMERY P et al.: Leflunomide in combination therapy. J Rheumatol 2004; 71 (Suppl.): 25-30.
63. KIELY P, JOHNSON D: Infliximab and leflunomide combination therapy in rheumatoid arthritis: an open-label study. Rheumatology 2002; 41: 631-7.
64. STRUPPLER C, THIES W, SCHATTENKIRCHNER M, KELLNER H: Safety and efficacy of leflunomide and infliximab in rheumatoid arthritis patients (abstract). Ann Rheum Dis 2002; 61 (Suppl): S388.
65. HANSEN KE, CUSH J, SINGHAL A et al.: The safety and efficacy of leflunomide in combination with infliximab in rheumatoid arthritis. Arthritis Rheum 2004; 51: 228-32.
66. GODINHO F, GODFRIN B, EL MAHOU S, NAVAUX F, ZABRANIECKI L, CANTAGRE A: Safety of leflunomide plus infliximab combination therapy in rheumatoid arthritis. Clin Exp Rheumatol 2004; 22: 328-30.
67. KALDEN JR, SMOLEN JS, EMERY P, VAN RIEL PL, DOUGADOS M, STRAND CV, BREEDVELD FC: Leflunomide in combination therapy (review article). J Rheumatol 2004; 71 (Suppl.): 25-30.
68. WEINBLATT ME, KREMER JM, COBLYN JS et al.: Pharmacokinetics, safety, and efficacy of combination treatment with methotrexate and leflunomide in patients with active rheumatoid arthritis. Arthritis Rheum 2002; 7: 132.
69. KREMER JM, GENOVESE MC, CANNON GW et al.: Concomitant leflunomide therapy in patients with active rheumatoid arthritis despite stable doses of methotrexate. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 2002; 137: 726-33.
70. KREMER J, GENOVESE M, CANNON GW et al.: Combination leflunomide and methotrexate therapy for patients with active RA failing MTX monotherapy: open-label extension of a randomized, double-blind, placebo-controlled trial. J Rheumatol 2004; 31: 1521-31.